[1] World Health Organization (WHO) (2010) The Global Plan to Stop TB 2011-2015. World Health Organization, Geneva.
[2] World Health Organization (WHO) (2010) Multidrug and Extensively Drug-Resistant TB (M/XDR-TB)-2010. Global Report on Surveillance and Response. World Health Organization, Geneva.
[3] European Centre for Disease Prevention and Control/World Health Organization Regional Office for Europe (2014) Tuberculosis Surveillance in Europe 2009. Stockholm, European Centre for Disease Prevention and Control, 2011. http://www.ecdc.europa.eu
[4] Direcção Geral de Saúde (2011) Programa Nacional de Luta contra a Tuberculose. Ponto de situação epidemiológica e de desempenho. Divisão de Doenças Transmissíveis.
[5] Administração Regional da Saúde no Norte, I.P. A Tuberculose na Região de Saúde do Norte 2000-2010. Ano 2011. Unidade de Vigilancia Epidemiológica.
[6] Programa Nacional de Luta contra a Tuberculose. Perfil de susceptibilidade aos antibióticos de estirpe Mycobacterium Tuberculosis—Sistema de notificação laboratorial 2009. Ano 2010. Administração Regional de Saúde do Norte.
[7] Yang, X., Li, Y., Wen, X., Wu, X. and Li, X. (2010) Risk Factors for Drug Resistance in Pulmonary Tuberculosis in Patients. JEBM, 3, 162-167.
[8] Caminero, J.A. (2010) Multidrug-Resistant Tuberculosis: Epidemiology, Risk Factors and Case Finding. International Journal of Tuberculosis and Lung Disease, 14, 382-390.
[9] Farazi, A., Sofian, M., Zarrinfan, N., Katebi, F., Hoseini, S. and Keshavarz, R. (2013) Drug Resistance Patterns and Associated Risk Factors of Tuberculosis in the Central Province of Iran. Caspian Journal of Internal Medicine, 4, 785-789.
[10] Suárez-Garcia, I., Rodrígues-Blanco, A., Vidal-Pérez, J.L., García-Viejo, M.A., Jaras-Hernandez, M.J., López, O., et al. (2009) Risk Factors for Multidrug—Resistant Tuberculosis in a Tuberculosis Unit in Madrid, Spain. European Journal of Clinical Microbiology Infectious Diseases, 28, 325-330.
http://dx.doi.org/10.1007/s10096-008-0627-y
[11] Faustini, A., Hall, A.J. and Perucci, C.A. (2006) Risk Factors for Multidrug Resistant Tuberculosis in Europe: A Systematic Review. Thorax, 61, 158-163. http://dx.doi.org/10.1136/thx.2005.045963
[12] Casal, M., Vaquero, M., Rinder, H., Tortoli, E., Grosset, J., Rusch-Gerdes, S., et al. (2005) A Case-Control Study for Multidrug-Resistant Tuberculosis: Risk Factors in Four European Countries. Microbial Drug Resistance, 11, 62-67. http://dx.doi.org/10.1089/mdr.2005.11.62
[13] Kliiman, M.D. and Altraja, A. (2009) Predictors of Extensively Drug-Resistant Pulmonary Tuberculosis. Annals of Internal Medicine, 150, 766-775.
http://dx.doi.org/10.7326/0003-4819-150-11-200906020-00004
[14] Lomtadze, N., Aspindzelasvili, R., Janjgava, M., Mirtskhulava, V., Wright, A., Blumberg, H.M. and Salakaia, A. (2009) Prevalence and Risk Factors for Multidrug-Resistant Tuberculosis in Republic of Georgia: A Population Based Study. The International Journal of Tuberculosis and Lung Disease, 13, 68-73.
[15] Liu, Q., Zhu, L., Shao, Y., Song, H., Li, G., Zhou, Y., et al. (2013) Rates and Risk Factors for Drug Resistance Tuberculosis in Northeastern China. BMC Public Health, 13, 1171.
http://dx.doi.org/10.1186/1471-2458-13-1171
[16] Flora, M.S., Amin, M.N., Karim, M.R., Afros, S., Islam, S., Alam, A., et al. (2013) Risk Factors of Multi-Drug-Resistant Tuberculosis in Bangladeshi Population: A Case Control Study. Bangladesh Medical Research Council Bulletin, 39, 34-41. http://dx.doi.org/10.3329/bmrcb.v39i1.15808
[17] Wang, K., Chen, S., Wang, X., Zhong, J., Wang, X., Huai, P., et al. (2014) Factors Contributing to the High Prevalence of Multidrug-Resistant Tuberculosis among Previously Treated Patients: A Case-Control Study from China. Microbial Drug Resistance, 20, 294-300.
[18] World Health Organization. (2009) Guidelines for Surveillance of Drug Resistance in Tuberculosis. 4th Edition, WHO, Geneva.
[19] Alisjahbana, B., Sahiratmadja, E., Nelwan, E.J., Purwa, A.M., Ahmad, Y., Ottenhoff, T.H., et al. (2007) The Effect of Type 2 Diabetes Mellitus on the Presentation and Treatment Response of Pulmonary Tuberculosis. Clinical Infectious Diseases, 45, 428-435. http://dx.doi.org/10.1086/519841
[20] Dooley, K. and Chaisson, R. (2009) Tuberculosis and Diabetes Mellitus: Convergence of Two Epidemics. The Lancet Infectious Diseases, 9, 737-746. http://dx.doi.org/10.1016/S1473-3099(09)70282-8
[21] Harries, A., Lin, Y., Satyanarayana, S., Lonnroth, K., Li, L., Wilson, N., et al. (2011) The Looming Epidemic of Diabetes-Associated Tuberculosis: Learning Lessons from HIV-Associated Tuberculosis. The International Journal of Tuberculosis and Lung Disease, 15, 1436-1444. http://dx.doi.org/10.5588/ijtld.11.0503
[22] Maurice, J. (2011) WHO Framework Target Tuberculosis-Diabetes Link. The Lancet, 378, 1209-1210. http://dx.doi.org/10.1016/S0140-6736(11)61527-4
[23] Baker, M., Harries, A., Jeon, C., Hart, J., Kapur, A., Lonnroth, K., et al. (2011) The Impact of Diabetes on Tuberculosis Treatment Outcomes: A Systematic Review. BMC Medicine, 9, 81.
http://dx.doi.org/10.1186/1741-7015-9-81
[24] Mi, F., Tan, S., Liang, L., Harries, A., Hinderaker, S., Lin, Y., et al. (2013) Diabetes Mellitus and Tuberculosis: Patterns of Tuberculosis, Two-Month Smear Conversion and Treatment Outcomes in Guangzhou, China. Tropical Medicine and International Health, 18, 1379-1385.
http://dx.doi.org/10.1111/tmi.12198
[25] Mdivani, N., Zangaladze, E., Volkova, N., Kourbatova, E., Jibuti, T., Shubladze, N., et al. (2008) High Prevalence of Multidrug-Resistant Tuberculosis in Georgia. International Journal of Infectious Diseases, 12, 635-644. http://dx.doi.org/10.1016/j.ijid.2008.03.012
[26] Duarte, R., Santos, A., Mota, M., Carvalho, A., Marques, A. and Barros, H. (2011) Involving Community Partners in the Management of Tuberculosis among Drug Users. Public Health, 125, 60-62.
http://dx.doi.org/10.1016/j.puhe.2010.09.002
[27] Deiss, R., Rodwell, T. and Garfein, R. (2009) Tuberculosis and Drug Use: Review and Update. Clinical Infectious Diseases, 48, 72-82. http://dx.doi.org/10.1086/594126
[28] Moonan, P., Quituga, T., Pogoda, J., Woo, G., Drewyer, G., Sahbazian, B., et al. (2011) Does Directly Observed Therapy (DOT) Reduce Drug Resistant Tuberculosis? BMC Public Health, 11, 19.
http://dx.doi.org/10.1186/1471-2458-11-19